Dasatinib (BMS-354825)

DRUG3 trials

Sponsors

M.D. Anderson Cancer Center, University of Pittsburgh

Conditions

Acute Myeloid LeukemiaAgnogenic Myeloid MetaplasiaHypereosinophilic SyndromeLeukemiaLeukemia, Myelomonocytic, ChronicLymphomaMalignant Solid TumourMastocytosis

Phase 1

Safety Study Of Cetuximab Plus Dasatinib (BMS-354825) in Treating Advanced Solid Malignancies

CompletedNCT00388427

University of PittsburghMalignant Solid Tumour

Start: 2007-06-30End: 2013-02-28Updated: 2015-05-28

Phase 2

Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)

CompletedNCT00255346

M.D. Anderson Cancer CenterAcute Myeloid Leukemia, Agnogenic Myeloid Metaplasia, Hypereosinophilic Syndrome +5

Start: 2005-11-15End: 2017-03-03Updated: 2025-12-30

Therapy of Chronic Lymphocytic Leukemia With Dasatinib (BMS-354825)

CompletedNCT00364286

M.D. Anderson Cancer CenterLeukemia, Lymphoma

Start: 2006-08-01End: 2012-11-01Updated: 2026-01-20